Role for interferon-γ inducible chemokines in endocrine autoimmunity: An expanding field

Journal of Endocrinological Investigation

Volumn 26, Issue 2, 2003, Pages 177-180

  Rotondi, M ^b   Lazzeri, E ^a   Romagnani, P ^a   Serio, Mario ^a  

^a UNIVERSITY OF FLORENCE   (Italy)

^b UNIVERSITY OF NAPLES FEDERICO II   (Italy)

Author keywords

Chemokines; Glandular autoimmunity; Graves' disease; Hashimoto; Type I diabetes

Indexed keywords

CHEMOKINE; CHEMOKINE RECEPTOR CXCR3; CYSTEINE; CYTOKINE; GAMMA INTERFERON INDUCIBLE CHEMOKINE; GAMMA INTERFERON INDUCIBLE CHEMOKINE CXCL10; GAMMA INTERFERON INDUCIBLE CHEMOKINE CXCL11; GAMMA INTERFERON INDUCIBLE CHEMOKINE CXCL9; UNCLASSIFIED DRUG;

AMINO TERMINAL SEQUENCE; AUTOIMMUNE DISEASE; AUTOIMMUNITY; CELL SECRETION; CORRELATION ANALYSIS; CYTOKINE PRODUCTION; CYTOKINE RELEASE; DISEASE ASSOCIATION; DISEASE DURATION; ENDOCRINE DISEASE; ENDOCRINE GLAND; EPITHELIUM CELL; GRAVES DISEASE; HASHIMOTO DISEASE; HUMAN; IMMUNE RESPONSE; IMMUNOHISTOCHEMISTRY; IMMUNOREGULATION; INSULIN DEPENDENT DIABETES MELLITUS; LYMPHOCYTE MIGRATION; NEGATIVE FEEDBACK; OVARY FOLLICLE CELL; PATHOGENESIS; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; RECEPTOR BINDING; REVIEW; STATISTICAL SIGNIFICANCE; TH1 CELL; TISSUE LEVEL;

EID: 0037316394     PISSN: 03914097     EISSN: None     Source Type: Journal    
DOI: 10.1007/BF03345149     Document Type: Review

References (15)

1. Zlotnik A., Yoshle O. Chemokines: A new classification system and their role in immunity. Immunity 2000, 12: 121-127.
2. Arenberg D.A., Polverini P.J., Kunkel S.L. et al. The role of CXC chemokines in the regulation of angiogenesis in non-small cell lung cancer. J. Leukoc. Biol. 1997, 62: 554-562.
3. Muller A., Homey B., Soto H. et al. Involvement of chemokine receptors in breast cancer metastasis. Nature 2001, 410: 50-56.
4. Rossi D, Zlotnik A. The biology of chemokines and their receptors. Annu. Rev. Immunol. 2000, 18: 217-242.
5. Cascieri M.A., Springer M.S. The chemokine/chemokine-receptor family: Potential and progress for therapeutic intervention. Curr. Opin. Chem. Biol. 2000, 4: 420-427.
6. Romagnani P., Annunziato F., Lasagni L. et al. Cell cycle dependent expression of CXC chemokine receptor 3 by endothelial cells mediates angiostatic activity. J. Clin. Invest. 2001, 107: 53-63.
7. Serio M. Interferon-γ induced chemochines: Impact on metabolic and endocrine diseases. Endocrinol. Invest. 2001, 24: 2 (abstract).
8. Gaciá-López M.A., Sancho D., Sánchez-Madrid F., Marazuela M. Thyrocytes from autoimmune thyroid disorders produce the chemokines IP-10 and Mig and attract CXCR3+ lymphocytes. J. Clin. Endocrinol. Metab. 2001, 86: 5008-5016.
9. Romagnani P., Lazzeri E., Lasagni L. et al. IP-10 and Mig production by glomerular cells in human proliferative glomerulonephritis and regulation by nitric oxide. J. Am. Soc. Nephrol. 2002, 13: 53-64.
10. Romagnani P., Rotondi M., Lazzeri E. et al. Expression of IP-10/CXCL10 and Mig/CXCL9 in the thyroid and increased serum levels of IP-10/CXCL10 in the serum of subjects with recent onset Graves' disease. Am. J. Pathol. 2002, 161: 195-206.
11. Romagnani S. The Th1/Th2 Paradigm in Disease. R.G. Sandes Company, Austin, Texas, 1996.
12. Aniszewski J.P., Valyasevi R.W., Bahn R.S. Relationship between disease duration and predominant orbital T cell subset in Graves' ophthalmopathy. J. Clin. Endocrinol. Metab. 2000, 85: 776-780.
13. Shimada A., Morimoto J., Kodama K. et al. Elevated serum IP-10 levels observed in type 1 diabetes. Diabetes Care 2001, 24: 510-515.
14. Nicoletti F., Conget I., Di Mauro M. et al. Serum concentrations of the interferon-gamma-inducible chemokine IP-10/CXCL10 are augmented in both newly diagnosed type I diabetes mellitus patients and subjects at risk of developing the disease. Diabetologia 2002, 45: 1107-1110.
15. Raz I., Elias D., Avron A., Tamir M., Metzger M., Cohen I.R. β-Cell function in new onset type 1 diabetes and immunomodulation with a heat shock protein peptide (DiaPep277): A randomized, double-blind, phase II trial. Lancet 2001, 358: 1749-1753.